Sexual Medicine Society of North America, Inc.

Main Menu

If you are an SMS member, we encourage you to post an article or references to interesting articles on this page. Please email your posting to info@smsna.info

Adelaide M. Arruda-Olson, MD, PhD; Douglas W. Mahoney, MS; Ajay Nehra, MD; Marilyn Leckel, RN; Patricia A. Pellikka, MD

Context: The relationship between sildenafil citrate use and reported adverse cardiovascular events in men with coronary artery disease(CAD) is unclear.

Objective: To evaluate the cardiovascular effects of sildenafil during exercise in men with CAD.

Design, Setting, and Subjects: Randomized, double-blind, placebo-controlled crossover trial conducted March to October 2000 at a US ambulatory-care referral center among 105 men with a mean (SD) age of 66 (9) years who had erectile dysfunction and known or highly suspected CAD.

Interventions: All patients underwent 2 symptom-limited supine bicycle echocardiograms separated by an interval of 1 to 3 days after receiving a single dose of sildenafil (50 or 100 mg) or placebo 1 hour before each exercise test.

Main Outcome Measures: Hemodynamic effects of sildenafil during exercise (onset, extent, and severity of ischemia) assessed by exercise echocardiography.

Results: Mean (SD) resting ejection fraction was 56% (7%) (range, 39%-68%). After sildenafil use, resting systolic blood pressure was reduced from 135 (19) mm Hg to 128 (17) mm Hg, for a mean change of -7 mm Hg (95% confidence interval [CI], -9 to -4 mm Hg; P<.001). After placebo use, the mean (SD) change was from 135 (20) mm Hg to 133 (19) mm Hg, a difference of -2 mm Hg (95% CI, -6 to 0.3 mm Hg; P = .08). The difference between mean change after sildenafil and placebo use was 4.3 (95% CI, 0.9-7.7; P = .01). Resting heart rate, diastolic blood pressure, and wall motion score index (a measure of the extent and severity of wall motion abnormalities) did not change significantly in either group. Exercise capacity was similar with sildenafil use (mean [SD], 4.5 [1.0] metabolic equivalents) and placebo use (mean [SD], 4.6 [1.0] metabolic equivalents; mean difference, 0.07; 95% CI, -0.06 to 0.19; P = .29). Exercise blood pressure and heart rate increments were similar. Dyspnea or angina developed in 69 patients who took sildenafil and 70 patients who took placebo (P = .89); exercise electrocardiography was positive in 12 patients (11%) who took sildenafil and 17 patients (16%) who took placebo (P = .09). Exercise-induced wall motion abnormalities developed in similar numbers of patients after sildenafil and placebo use (84 and 86 patients, respectively; P = .53). Wall motion score index at peak exercise was similar after sildenafil and placebo use (mean [SD], 1.4 [0.4] vs 1.4 [0.4]; mean difference, 0.01; 95% CI, -0.01 to 0.03; P = .40).

Conclusion: In men with stable CAD, sildenafil had no effect on symptoms, exercise duration, or presence or extent of exercise-induced ischemia, as assessed by exercise echocardiography.

JAMA. 2002;287:719-725

Author/Article Information

Author Affiliations: Division of Cardiovascular Diseases and Internal Medicine (Drs Arruda-Olson and Pellikka and Ms Leckel) and Departments of Biostatistics (Mr Mahoney) and Urology (Dr Nehra), Mayo Clinic and Mayo Foundation, Rochester, Minn.

Corresponding Author and Reprints: Patricia A. Pellikka, MD, Division of Cardiovascular Diseases and Internal Medicine, MayoClinic, 200 First St SW, Rochester, MN 55905 (e-mail:pellikka.patricia@mayo.edu).

Author Contributions: Study concept and design: Arruda-Olson, Mahoney, Nehra, Pellikka.

Acquisition of data: Leckel, Pellikka.
Analysis and interpretation of data: Arruda-Olson, Mahoney, Nehra, Leckel, Pellikka.
Drafting of the manuscript: Arruda-Olson, Mahoney, Nehra, Pellikka.
Critical revision of the manuscript for important intellectual content: Mahoney, Leckel, Pellikka.
Statistical expertise: Mahoney
Obtained funding: Arruda-Olson, Pellikka
Administrative, technical, or material support: Pellikka
Study supervision: Pellikka

Funding/Support: The study was supported by grants from the Mayo Foundation and from the American Heart Association, Northland Affiliate. Dr Arruda-Olson was supported by grants from the CAPES Foundation (Fundação Coordenação de Aperfeiçoamento de Pessoal de Nível Superior), Brasília, Brazil, and from the Mayo Foundation.

For more information, please visit: http://jama.ama-assn.org/cgi/content/short/287/6/719


References to Interesting Articles

1. Arruda-Olson, A.M., Mahoney, D.W., Nehra, A., Leckel, M., Pellikka, P.P. "Cardiovascular Effects of Sildenafil During Exercise in Men With Known or Probable Coronary Artery Disease: A Randomized Crossover Trial." The Journal of the American Medical Association 287(6):719-725, February 2002. 2. Gholami, S.S., Lue, T.F. "Correction of Penile Curvature Using 16-Dot Plication Technique: Review of 132 Patients." The Journal of Urology 176(5):2066-2069, May 2002.

Our Services

About SMSNA

Established in 1994, our objective has been to promote, encourage, and support the highest standards of practice, research, education, and ethics in the study of the anatomy, physiology, pathophysiology, diagnosis, and treatment...

~ Read More

Contact Us

SMSNA Executive Office
c/o Status Plus
+1 (952) 683 1917
+1 (612) 808 0491
info@smsna.org

Address
14305 Southcross Dr
Suite 100
Burnsville MN, 55306